接受经皮冠状动脉介入治疗的患者中使用坎格瑞洛联用与不联用糖蛋白IIb/IIIa抑制剂
该汇总分析纳入三项CHAMPION试验中接受PCI并用药的24902例患者,比较坎格瑞洛与氯吡格雷在联用或不联用GPI亚组中的疗效与安全性。联用GPI者主要复合终点4.9% vs 6.5%(OR 0.74,95%CI 0.55-1.01),未联用者3.6% vs 4.4%(OR 0.82,95%CI 0.72-0.94),交互P=0.55。GPI使用与两个治疗组出血风险增加相关。
要点
- 坎格瑞洛降低缺血复合终点的效应在联用与不联用GPI患者中均维持。
- 联用GPI者主要终点OR 0.74(95%CI 0.55-1.01),未联用者OR 0.82(95%CI 0.72-0.94)。
- GPI使用与两个治疗组出血风险增加相关,坎格瑞洛未增加GUSTO严重/危及生命出血。
核心结论
- 坎格瑞洛在接受PCI患者中减少缺血并发症的疗效不受是否使用GPI影响。
- GPI使用与 substantially higher 出血率相关,无论随机分配至坎格瑞洛还是氯吡格雷。
研究设计与样本
- 三项CHAMPION试验的汇总患者水平分析,纳入接受PCI并接受研究药物的所有随机患者24902例。
- 仅允许 bailout/rescue GPI使用,但CHAMPION PCI中常规或 bailout/rescue GPI使用由中心研究者决定。
- 主要疗效终点为随机化后48小时全因死亡、心肌梗死、缺血驱动血运重建或支架血栓的复合终点。
主要发现
- 共3173例患者(12.7%)接受GPI,最常用为依替巴肽(69.4%)。
- 联用GPI者主要复合终点:坎格瑞洛4.9% vs 氯吡格雷6.5%(OR 0.74,95%CI 0.55-1.01)。
- 未联用GPI者主要复合终点:坎格瑞洛3.6% vs 氯吡格雷4.4%(OR 0.82,95%CI 0.72-0.94;交互P=0.55)。
- 联用GPI者GUSTO严重/危及生命出血:坎格瑞洛0.4% vs 氯吡格雷0.5%(OR 0.71,95%CI 0.25-1.99)。
- 未联用GPI者GUSTO严重/危及生命出血:坎格瑞洛0.2% vs 氯吡格雷0.1%(OR 1.56,95%CI 0.80-3.04;交互P=0.21)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cangrelor, an intravenous, reversible P2Y12 antagonist, is approved for use in patients undergoing percutaneous coronary intervention (PCI). OBJECTIVES: This study sought to evaluate the efficacy and safety of cangrelor compared with clopidogrel in subgroups that did and did not receive glycoprotein IIb/IIIa inhibitors (GPIs). METHODS: This pooled, patient-level analysis of the 3 CHAMPION (Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) trials analyzed all randomized patients who underwent PCI and received the study drug (n = 24,902). Only bailout/rescue GPI use was permitted, except in CHAMPION PCI, in which routine or bailout/rescue GPI use was at the site investigator's discretion. The primary efficacy endpoint was the composite of all-cause mortality, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 h after randomization. RESULTS: Overall, 3,173 patients (12.7%) received a GPI, most commonly eptifibatide (69.4%). Despite variation in indications for GPIs, baseline characteristics were well balanced between the cangrelor and clopidogrel arms in subsets receiving and not receiving GPIs. Rates of the primary composite endpoint were lower with cangrelor compared with clopidogrel in patients who did (4.9% vs. 6.5%; odds ratio [OR]: 0.74; 95% confidence interval [CI]: 0.55 to 1.01) or did not receive a GPI (3.6% vs. 4.4%; OR: 0.82; 95% CI: 0.72 to 0.94; Pint = 0.55). Cangrelor did not increase the primary safety endpoint, GUSTO-defined severe/life-threatening bleeding, in patients who did (0.4% vs. 0.5%; OR: 0.71; 95% CI: 0.25 to 1.99) or did not receive GPIs (0.2% vs. 0.1%; OR: 1.56; 95% CI: 0.80 to 3.04; Pint = 0.21). GPI use was associated with increased risk of bleeding in both treatment arms. CONCLUSIONS: Cangrelor's efficacy in reducing ischemic complications in patients undergoing PCI was maintained irrespective of GPI administration. GPI use was associated with substantially higher bleeding rates, regardless of the randomization to cangrelor or clopidogrel. (A Clinical Trial to Demonstrate the Efficacy of Cangrelor [PCI]: NCT00305162; Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition [PLATFORM]: NCT00385138; A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI] [CHAMPION PHOENIX] [CHAMPION]: NCT01156571).
引用
- Vaduganathan M, Harrington RA, Stone GW, et al. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017. PMID: 28081827. doi:10.1016/j.jacc.2016.10.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。